MA AG Secures $17.85M in Generic Drug Price Fixing Settlements

Eligibility for Compensation Announced

Feb. 3, 2026 at 11:15am

Got story updates? Submit your updates here. ›

The Massachusetts Attorney General's office has secured $17.85 million in settlements with pharmaceutical companies Lannett Company, Inc. and Bausch Health US, LLC and Bausch Health Americas, Inc. The settlements resolve allegations of a long-running conspiracy to artificially inflate and manipulate prices for numerous generic prescription drugs. Consumers who purchased certain generic medications from these companies between May 2009 and December 2019 may be eligible for restitution.

Why it matters

These multi-state actions demonstrate a concerted effort to address concerns about anti-competitive practices within the pharmaceutical industry and their impact on drug pricing. The scope of the investigations, involving numerous companies and executives, suggests a widespread issue that has driven up costs for consumers.

The details

The agreements stem from accusations that Lannett and Bausch engaged in practices designed to reduce competition and restrain trade. As a result of the settlements, Massachusetts will receive $203,410, and restitution may be available to eligible consumers within the state. The settlements follow prior agreements with Apotex and Heritage, which totaled $49.1 million. Both Lannett and Bausch have agreed to internal reforms to ensure fair competition and compliance with antitrust laws.

  • The settlements cover generic drugs manufactured between May 2009 and December 2019.
  • The Massachusetts Attorney General's office filed the lawsuit in February 2026.

The players

Massachusetts Attorney General Andrea Joy Campbell

The Massachusetts Attorney General who has led the coalition of states in securing the settlements and filing the lawsuit against Novartis and Sandoz.

Lannett Company, Inc.

One of the pharmaceutical companies that reached a $17.85 million settlement with the coalition of states over allegations of price fixing and anti-competitive practices.

Bausch Health US, LLC and Bausch Health Americas, Inc.

The other pharmaceutical company that reached a $17.85 million settlement with the coalition of states over allegations of price fixing and anti-competitive practices.

Novartis

The pharmaceutical company that has been named in a new lawsuit filed by the Massachusetts Attorney General and a coalition of 42 states and territories, alleging a systemic effort to conspire with other generic manufacturers to fix prices, allocate markets, and rig bids for 31 different generic drugs.

Sandoz

The generic drug subsidiary of Novartis that has been named in the new lawsuit filed by the Massachusetts Attorney General and a coalition of 42 states and territories.

Got photos? Submit your photos here. ›

What they’re saying

“These multi-state actions demonstrate a concerted effort to address concerns about anti-competitive practices within the pharmaceutical industry and their impact on drug pricing.”

— Samantha Carter, oversees all editorial operations at Newsy-Today.com (Newsy-Today.com)

What’s next

The lawsuit against Novartis and Sandoz is ongoing, and it remains to be seen whether further settlements will be reached or if the case will proceed to trial. It is also possible that additional pharmaceutical companies could become targets of similar investigations.

The takeaway

The settlements and ongoing legal actions highlight the widespread issue of anti-competitive practices in the pharmaceutical industry that have driven up costs for consumers. The efforts by state attorneys general demonstrate a commitment to holding companies accountable and seeking restitution for impacted consumers.